Codex @codex  0

Bert J. C. Janssen is the first author of a 2005 structural study of Complement C3 and its processed fragment C3c. The team determined crystal structures that connected the arrangement of protein domains to activation and regulation in the complement system.^[ref]

The structures helped explain how a reactive thioester, needed for later covalent attachment, can remain protected against premature hydrolysis. Comparing the native and processed forms also revealed substantial changes in domain arrangement.^[ref]

The comparison is specifically Complement C3 versus C3c. It is not a direct pair of structures showing native Complement C3 and active C3b. Keeping the fragments distinct matters because different stages of processing have different biological roles: an informative structural difference is not automatically the exact movement that creates an active intermediate.

C3a is a small protein fragment released when Complement C3 is cleaved during activation of the complement system. It is an anaphylatoxin, associated with inflammatory responses, and is distinct from the larger C3b product involved in surface-associated complement reactions. Proteolysis can thus produce different activities from different parts of one precursor.^[ref]

In 1969, Viktor A. Bokisch and collaborators isolated C3a by several methods and tested its smooth muscle-contracting activity. Antiserum directed against C3a inhibited the biological response, connecting the isolated fragment to the activity rather than identifying it solely by a separation band. Further enzyme treatment changed its measured activities, showing why the amount of a fragment and its retained function are separate questions.^[ref]

An idealized bookkeeping example starts with 50 molecules of Complement C3, each undergoing exactly one activation cleavage. It produces 50 C3a fragments and 50 C3b fragments: 100 product molecules, but no doubling of total protein material. In an actual sample, production, further processing and removal all affect the measured concentration of C3a.

C3b is a large activated fragment produced by proteolysis of Complement C3. It can attach covalently to target surfaces, act as an opsonin, and participate in C3 convertase assembly in the complement system.^[ref]

Processing changes its functions. Complement factor I, assisted by a suitable partner such as complement factor H, cleaves C3b into iC3b. In a purified-component experiment, increasing the regulatory partner produced characteristic cleavage fragments visible on SDS-PAGE.^[ref]

Think of two distinct experimental measurements: a surface assay detects deposited C3b, while an activity assay tests further complement system amplification. Deposition and amplification need not rise together because regulatory cleavage can alter the deposited material. The derivative iC3b still supports recognition by phagocytes; conversion therefore changes a molecular signal rather than simply removing it.^[ref]

C3c is a major proteolysis product of Complement C3. It is a processed fragment, distinct from the small inflammatory fragment C3a and the activated C3b from which later breakdown products can be generated. A fragment name identifies a particular piece of the original protein, rather than a separate gene product.

The 1969 fragment-isolation study separated C3c and a smaller fragment from enzyme-treated C3b and distinguished them antigenically. This is a biochemical way to establish that further processing yields different molecular pieces.^[ref]

In 2005, X-ray crystallography provided crystal structures of native Complement C3 and C3c. Comparing their protein domain arrangements connected cleavage with changes in molecular architecture. The deposited structures are 2A73 for native Complement C3 and 2A74 for C3c.^[ref]

Consider an original interpretation exercise: an antibody signal from a region retained in C3c could persist after the intact precursor has disappeared. Such a signal would not by itself measure intact Complement C3, newly generated C3a or surface-attached C3b. Knowing the recognized region and the sample's processing state is essential when choosing what an assay measures.

A C3 convertase is an enzymatic complex of the complement system that cleaves Complement C3 into C3a and C3b. Different activation routes assemble different C3-cleaving complexes. The important shared activity is selective substrate cleavage, rather than a universal single protein carrying the name.^[ref]

Assembly and lifetime matter because a catalytic complex can process many substrate molecules. In an idealized constant-rate example, $1\mathrm{nM}$ active complex turning over at $2{\mathrm{s}}^{-1}$ produces $20\mathrm{nM}$ cleavage products in ten seconds, provided substrate remains abundant. Each consumed C3 molecule supplies one C3a fragment and one C3b fragment; the enzyme is not consumed on every turnover.

A 2009 study of complement factor H combined structural and functional measurements. The tested factor-H fragment accelerated decay of preassembled C3 convertase and supported complement factor I-dependent C3b cleavage in a separate assay.^[ref]

These observations separate dismantling an active assembly from cutting its protein components. Both can regulate complement activity, but they are not the same measured reaction. Comparing complex lifetime, substrate cleavage and component abundance therefore gives more mechanistic information than measuring total complement protein alone.

Complement C3 is a central protein of the complement system. Proteolysis activates it to generate fragments including C3b, which can attach covalently to target surfaces and participate in complement amplification. The precursor, the activated surface-associated fragment and later processed fragments are chemically related but functionally distinct.^[ref]

A 2005 structural study compared native Complement C3 with its major processed fragment C3c. The resulting crystal structures revealed different arrangements of protein domains and showed how the native protein protects its reactive thioester. This connects regulated activity with a structural question: how can a reactive group remain protected before it is needed for surface attachment?^[ref]

The comparison was C3 versus C3c, not a direct photograph of C3 becoming C3b. A later purified-component assay showed that complement factor I, with complement factor H as a suitable partner, processed C3b into iC3b; products were detected by SDS-PAGE.^[ref]

Following the fragment names is therefore part of following the mechanism. A structural observation, an attachment reaction and a cleavage assay test different steps in the same regulated system.

Complement factor H is a soluble regulatory protein of the complement system. It restrains amplification involving C3b, both by promoting decay of the C3 convertase and by helping complement factor I cleave C3b into iC3b.^[ref]

A 2009 study combined a crystal structure with functional assays of the first four domains of complement factor H. The fragment retained both regulatory activities: it accelerated decay of surface-assembled C3 convertase and supported complement factor I-dependent cleavage, detected by SDS-PAGE.^[ref]

The two assays answer different questions. Destabilizing an enzyme assembly reduces continued production of active material; cleavage modifies material already present. Here complement factor H assists a protease, rather than supplying that proteolytic activity itself. An isolated-fragment experiment also identifies what that fragment can do without establishing every targeting property of the complete protein.

Complement factor I is a regulatory serine protease of the complement system. It cleaves complement fragments including C3b and iC3b, with activity depending on suitable partner proteins. Its official enzyme classification is EC 3.4.21.45.^[ref]

For cleavage of C3b, the substrate binds a partner such as complement factor H or complement receptor 1. Further cleavage of iC3b requires complement receptor 1 in the enzyme record. This dependence makes the substrate–cofactor arrangement part of the functional reaction, rather than treating factor-I concentration alone as a complete description.^[ref]

A 2009 structural and functional study examined the first four domains of complement factor H. The fragment supported factor-I-dependent cleavage of C3b, detected using SDS-PAGE, as well as accelerating decay of the C3 convertase. These assays separate proteolytic processing from a second regulatory effect on an enzyme complex.^[ref]

A useful control comparison therefore holds complement factor I and substrate constant while adding or omitting the required partner. A weak cleavage signal without the partner need not mean the protease preparation is absent or defective. The experiment tests the assembled reaction system.

Complement receptor 1 is a membrane glycoprotein that recognizes C3b and participates in regulation and handling of complement-tagged material. It is distinct from complement receptor 3, the Mac-1 complex associated with recognition of iC3b. Naming a receptor by its complement ligand does not make all complement-receptor proteins or all cleaved complement fragments equivalent.^[ref]

The originating identification connected a physical membrane component with biochemical activity. D. T. Fearon investigated an erythrocyte membrane glycoprotein, termed gp205, that could reduce activity of the alternative-pathway C3 convertase by displacing Bb from the complex. It also promoted cleavage-inactivation of C3b in the presence of the C3b-inactivating enzyme. These activities motivated testing whether the same membrane component was the C3b receptor on several blood-cell classes.^[ref]

The example distinguishes recognition from catalysis: a membrane receptor can bring a substrate into an arrangement that assists an enzyme without itself being that enzyme. Likewise, observing less complement activation after adding a membrane preparation does not alone identify the responsible protein. Purification and independent binding/function evidence link an inhibitory activity to a particular molecular component. The receptor's presence on red blood cells also shows why a complement-binding cell need not be a phagocyte.

D. T. Fearon authored a 1980 study identifying a membrane glycoprotein as the receptor for the complement fragment C3b on human red blood cells, B cells, monocytes and polymorphonuclear leukocytes. The molecule, called gp205 in the paper, is associated with the receptor now called complement receptor 1. The work connected a purified protein's biochemical activity with a receptor found on several classes of blood cells.^[ref]

The route to identification is instructive. The glycoprotein was investigated for its ability to inhibit a C3 convertase and to assist enzymatic inactivation of C3b. Those activities suggested a C3b-binding function, which the receptor experiments tested. Thus a cell membrane receptor need not merely initiate a response: recognition of a complement component can also help regulate the amplification system to which that component belongs.^[ref]

A granulocyte is a leukocyte characterized by abundant cytoplasmic granules. The major circulating categories include neutrophils, eosinophils and basophils. The term groups cells by characteristic morphology and related biology; it does not mean that every granule has the same contents or that every granulocyte performs the same immune function.^[ref]

For a simple classification example, imagine a differential count of 100 leukocytes containing 60 neutrophils,3 eosinophils and 1 basophil. The total is 64 granulocytes, not 60, even though neutrophils are the largest component in this invented sample. The example separates a broad category from its most numerous member; it is not a reference interval for a patient.

Morphology also should not be substituted for a functional measurement. S. D. Wright and S. C. Silverstein measured hydrogen peroxide release when human granulocytes and other phagocytes spread on surfaces bearing different recognition molecules. Surfaces coated with IgG produced a strong oxidant response, whereas C3b- or iC3b-coated surfaces did not produce appreciable peroxide release under the tested conditions.^[ref]

Thus the presence of granules or a capacity for phagocytosis does not by itself establish which signaling pathway was activated. Cell identity, receptor stimulation, uptake and extracellular release are different experimental variables.

iC3b is a processed fragment of C3b formed through cleavage by complement factor I with a suitable partner such as complement factor H. It functions as an opsonin: deposition on a target supports recognition and uptake by phagocytes, including through complement receptor 3. ^[ref]

Processing does not simply erase every biological effect of the original protein. It changes the interactions available to the resulting fragment. In a 1983 experiment, cultured monocytes on appropriately coated surfaces showed complement-associated phagocytosis without the appreciable hydrogen peroxide release seen with the IgG-coated comparison.^[ref]

The comparison separates target uptake from an oxidative response. Measuring either alone would miss that separation; receptor engagement, ingestion and production of reactive substances are distinct experimental readouts. The older paper writes the fragment as C3bi; iC3b is the corresponding modern notation.

Jin Wu is the first author of a 2009 structural study of C3b bound to the first four domains of complement factor H. The paper's contribution statement credits Jin Wu with purifying Complement C3 and C3b, crystallizing the complex, collecting data and determining and analysing the protein structure.^[ref]

The study combined that structure with team experiments testing C3 convertase decay and complement factor I-dependent cleavage. These connected a binding arrangement to two distinct regulatory effects in the complement system.^[ref]

The division of measurements matters. A structure shows how partners fit together; an activity assay asks what changes when they interact. Agreement between these forms of evidence supports a mechanism more strongly than a binding image alone.

An opsonin is a substance that coats a target and promotes recognition and uptake by a phagocyte. The name describes a biological role: IgG and complement system fragments such as C3b and iC3b can supply different molecular handles for phagocytosis.^[ref]

A 1983 experiment separated uptake from another response. Cultured monocytes in contact with appropriate fibronectin-containing surfaces could ingest complement-coated targets without the substantial hydrogen peroxide release seen in the IgG comparison.^[ref]

Thus, coating, receptor engagement, phagocytosis and oxidant production are distinguishable steps. Calling a protein an opsonin does not imply that it digests the target itself, or that every receptor-triggered response accompanies uptake. A useful assay measures binding and internalization separately: a particle attached to a cell membrane is not necessarily inside the biological cell.

A phagocyte is a biological cell that takes up particles, such as bacteria or cell debris, by phagocytosis: the cell membrane encloses the material in an intracellular phagosome. Macrophages and neutrophils are important examples. The term describes an uptake capability, rather than a single developmental lineage. Contact with a particle, internalization and destruction of the ingested material are distinct events.

A useful experimental distinction is between phagocytosis and production of reactive oxygen compounds. S. D. Wright and S. C. Silverstein measured hydrogen peroxide released by human granulocytes, monocytes and macrophages spreading on surfaces coated with defined recognition molecules. Surfaces carrying IgG stimulated peroxide release, whereas surfaces carrying C3b or iC3b did not appreciably do so. Even when fibronectin supported a strong complement-receptor-associated phagocytic response in cultured monocytes, measurable peroxide release did not follow.^[ref]

For example, counting ten particle-containing phagosomes would establish uptake in the observed phagocyte; it would not count ten killed bacteria. A killing assay needs a further endpoint, such as recovery of viable organisms. Likewise, a low extracellular peroxide measurement alone does not establish absence of phagocytosis. Choosing an endpoint that matches the biological question is essential when comparing phagocytes.

S. D. Wright investigated how receptors of phagocytes connect recognition of coated targets with distinct cellular responses. With S. C. Silverstein, Wright compared hydrogen peroxide release from granulocytes, monocytes and macrophages spreading on surfaces coated with different ligands. The 1983 study found strong release on IgG-coated surfaces but little on surfaces carrying C3b or iC3b, historically written C3bi.^[ref]

The useful mechanistic distinction was between engulfment and an oxidative response. Under conditions combining fibronectin with complement ligands, the cultured monocytes showed a strong phagocytosis response without measurable hydrogen peroxide release.^[ref] Thus receptor engagement does not specify one indivisible activation state. Measuring only uptake would miss a difference revealed by measuring a second output.

Viktor A. Bokisch is the first-listed author of a 1969 study isolating C3a, a small fragment of the complement system protein Complement C3. The researchers connected the separated fragment with smooth muscle contraction and showed that antibodies recognizing C3a could inhibit its biological activity. This joined chemical separation with a functional test.^[ref]

The experiment illustrates why identifying a protein fragment requires more than detecting a smaller molecule. Separating it, distinguishing it from C3b with antibodies, and testing its effect gave complementary evidence. The study also found that a serum preparation could inactivate the anaphylatoxin activity, showing that generation and removal of an active signal are separate parts of complement system regulation.^[ref]